AJH: Prediction of survival and association of characteristics with intensive chemotherapy in acute myeloid leukemia

Advances in intensive chemotherapy and supportive care have improved survival in newly diagnosed acute myeloid leukemia (AML)

The researchers analyzed survival as a treatment endpoint in 3,728 patients with newly diagnosed AML who received intensive chemotherapy from 1980 to 2021

In the training cohort, multivariate analysis identified 12 consistent poor prognostic variables independently associated with poorer survival: older age, treatment-related myeloid neoplasms, poorer performance status, cardiac comorbidities, leukocytosis, anemia , thrombocytopenia, elevated creatinine and lactate dehydrogenase, cytogenetic abnormalities, and infection at diagnosis , except unexplained fever

Older age, treatment-related bone marrow neoplasms, poor performance status, cardiac comorbidities, leukocytosis, anemia, thrombocytopenia, elevated creatinine and lactate dehydrogenase, cytogenetic abnormalities, and infection at diagnosis , but Unexplained fever is excluded

Figure 1: Survival by risk group in training (1A) and validation (1B)

Figure 1: Survival by risk group in training (1A) and validation (1B)

They divided patients into four prognostic groups, good (7%), moderate (43%), poor (39%), and very poor (11%), with estimated 5-year survival rates of 69%, 36%, and 13%, respectively and 3% (p<0.

Table: Suggested Survival Prognostic Risk Classification: 3A) Score, 3B) Risk Classification and Survival

Table: Suggested Survival Prognostic Risk Classification: 3A) Score, 3B) Risk Classification and Survival

In the subset of patients with molecular mutational profiles, mutational profiles NPM1 (favorable), PTPN11 , and TP53 (all unfavorable) mutations were added as molecular prognostic factors after accounting for the influence of previously identified factors

NPM1 PTPN11 TP53

This is the largest analysis of prognostic factors for survival in AML with intensive high-dose cytarabine-based chemotherapy to date

This is the largest prognostic factor analysis to date of high-dose cytarabine-based intensive chemotherapy for survival in AML

 

Original source:

Original source:

Sasaki, K.

Sasaki, K.
, Ravandi, F.
, Kadia, T.
, DiNardo, C.
, Borthakur, G.
, Short, N.
, Jain, N.
, Daver, N.
, Jabbour, E.
, Garcia-Manero, G .
, Khoury, J.
, Konoplev, S.
, Loghavi, S.
, Patel, K.
, Bravo, GM, Masarova, L.
, Konopleva, M.
and Kantarjian, H.
(2022), Prediction of Survival with Intensive Chemotherapy in Acute Myeloid Leukemia.
Am J Hematol.
Accepted Author Manuscript.
https://doi.
org/10.
1002/ajh.
26557.
Sasaki, K.
, Ravandi, F.
, Kadia, T.
, DiNardo, C.
, Borthakur, G .
, Short, N.
, Jain, N.
, Daver, N.
, Jabbour, E.
, Garcia-Manero, G.
, Khoury, J.
, Konoplev, S.
, Loghavi, S.
, Patel, K.
, Bravo , GM, Masarova, L.
, Konopleva, M.
and Kantarjian, H.
(2022), Prediction of Survival with Intensive Chemotherapy in Acute Myeloid Leukemia.
Am J Hematol.
Accepted Author Manuscript.
https://doi.
org/10.
1002/ ajh.
26557.


Leave a message here